This is an open-label, Phase II, single center trial of pembrolizumab (MK-3475), lenalidomide
and dexamethasone in subjects with high risk Multiple Myeloma (hrMM) post high-dose
chemotherapy with autologous stem cell transplantation (ASCT).
Patients with high-risk MM defined as those with one of the following abnormalities who have
undergone induction therapy followed by single or tandem melphalan -based ASCT will be